Pharmaceutical companies are reportedly enhancing their intellectual property protections as they face growing competition from China. This strategic move reflects the industry's response to a rapidly evolving global market.
The FDA has introduced new pathways that may influence how drugmakers approach development and regulation. These changes could have significant implications for both domestic and international competition.
Additionally, the status of animal testing remains a critical topic within the biotech sector, as companies navigate ethical considerations alongside regulatory requirements.